WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities fraud. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact the firm before August 3, 2026. The lawsuit alleges that GeneDx made false and misleading statements regarding its financial performance, including a drop in adjusted gross margin and a significant impairment charge, leading to investor losses.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of GeneDx Holdings Corp. (NASDAQ: WGS) to join a class action lawsuit alleging securities fraud. The lawsuit claims GeneDx made false and misleading statements between April 16, 2025, and May 4, 2026, leading to investor damages. This comes after the company reported a drop in gross margin, lowered earnings projections, and a significant impairment charge related to Fabric Genomics.
CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) who suffered losses between April 16, 2025, and May 4, 2026, about the August 3, 2026, deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made misleading statements regarding the importance of Fabric Genomics, the durability of reimbursement rates, and the company's gross margins, leading to a significant stock price drop after Q1 2026 financial results and guidance cuts were announced. Investors are encouraged to contact the firm to discuss their legal options.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings
The Rosen Law Firm is encouraging investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, to secure counsel before the August 3, 2026, lead plaintiff deadline. The firm reminds investors they may be entitled to compensation due to alleged misrepresentations and omissions by GeneDx regarding the impact of its Fabric acquisition. The lawsuit claims that GeneDx's statements about Fabric improving financials and creating efficiencies were false, as defendants allegedly knew of significant problems in Fabric's viability.
INVESTOR DEADLINE ALERT: GeneDx Holdings Corp. (WGS) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for investors who bought stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false statements regarding the viability of its acquisition of Fabric Genomics, which resulted in a significant stock drop. Investors have until August 3, 2026, to seek lead plaintiff status.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
The Rosen Law Firm is reminding investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GeneDx made misrepresentations and omissions regarding the impact of its Fabric acquisition on the company's financials and operations. Investors are encouraged to secure counsel to potentially recover losses.
CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is reminding GeneDx (WGS) investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that GeneDx, its executives, made misleading statements regarding Fabric Genomics' importance, reimbursement rates, and gross margins, leading to a significant stock drop on May 4, 2026. Investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx and its officers made materially false and misleading statements regarding the importance of Fabric Genomics, the company's margins, and average reimbursement rates, leading to investor harm. Bronstein, Gewirtz & Grossman, LLC is representing the investors and encourages those who suffered losses to consider joining the case as lead plaintiff by August 3, 2026.
WGS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS)
Faruqi & Faruqi, LLP is reminding investors of GeneDx (WGS) about a securities class action lawsuit deadline on August 3, 2026. This lawsuit alleges that GeneDx and its executives made misleading statements regarding their Fabric Genomics acquisition and reimbursement rates, leading to a significant stock price drop on May 4, 2026, after negative Q1 financial results and reduced guidance were announced. Investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
WGS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages WGS Investors With Losses to Contact the Firm
Kessler Topaz Meltzer & Check, LLP (KTMC) has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics, which led to a significant drop in stock price. Investors who incurred losses are encouraged to contact KTMC by the lead plaintiff deadline of August 3, 2026.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC ("KSF") has announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), reminding investors that they have until August 3, 2026, to file lead plaintiff applications. The lawsuit alleges that GeneDx and its executives failed to disclose material information, violating federal securities laws, leading to a 49.2% stock price drop after the company reported missed revenue estimates, lowered guidance, and a significant impairment loss related to its Fabric Genomics acquisition. Investors who purchased shares between April 16, 2025, and May 4, 2026, and experienced substantial losses, are encouraged to contact KSF for legal counsel.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) securities between April 16, 2025, and May 4, 2026, to join a class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements, particularly regarding a drop in adjusted gross margin, lowered projected earnings, and a $31.3 million impairment related to Fabric Genomics reported on May 4, 2026. Investors have until August 3, 2026, to contact the firm to participate.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines - WGS
Pomerantz LLP
GeneDx (WGS) president receives 35,441 restricted stock units in new equity award
GeneDx Holdings Corp. President Mark A. Gardner was granted 35,441 restricted stock units (RSUs), which convert into Class A common stock without a cash payment. These RSUs will vest in 25% increments annually starting July 1, 2027, contingent on his continued employment. This award is a form of compensation rather than a market transaction.
GeneDx Holdings Corp. (WGS) Class Action Lawsuit Seeks Recovery for Investors; August 3, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false or misleading statements regarding the viability of its acquisition of Fabric Genomics. Investors have until August 3, 2026, to seek lead plaintiff status in the lawsuit following a significant drop in GeneDx's share price after it announced an impairment loss related to Fabric Genomics.
WGS Stockholders Have Rights – If You Lost Money Investing
Robbins LLP is reminding stockholders of GeneDx Holdings Corp. (WGS) that a class action lawsuit has been filed for investors who purchased stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx misled investors about the positive impact of its acquisition of Fabric Genomics, with the company's stock price dropping significantly after revealing an impairment loss related to Fabric and lowered revenue guidance. Shareholders have until August 3, 2026, to file as lead plaintiff.
WGS Stockholders Have Rights – If You Lost Money Investing
Robbins LLP has filed a class action lawsuit on behalf of investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx misled investors about the positive impact of its Fabric Genomics acquisition. After reporting a significant revenue miss, lowered guidance, and a $31.2 million impairment related to Fabric, GeneDx's stock price dropped by 49.2%.
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) after a substantial stock collapse and a $31.2 million impairment charge related to its Fabric Genomics acquisition. The suit alleges GeneDx misled investors about the acquisition's synergy and future profitability, leading to a massive increase in net loss. The firm is also looking into whether a recent change in leadership is connected to the alleged failures.
WGS DEADLINE: Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) about an upcoming securities class action deadline of August 3, 2026. The lawsuit targets two senior executives, Katherine Stueland (CEO) and Kevin Feeley (CFO), as individual defendants for alleged investor losses stemming from reimbursement weakness and underperformance of Fabric Genomics. Investors who purchased shares between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm to determine eligibility for recovery.
GENEDX HOLDINGS CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 3, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
Bernstein Liebhard LLP reminds investors of GeneDx Holdings Corp. (NASDAQ: WGS) that they have until August 3, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that the company made false and misleading statements between April 16, 2025, and May 4, 2026, leading to artificially inflated stock prices and investor losses. Investors who suffered losses and purchased shares during this period are encouraged to contact the law firm.
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GeneDx Holdings Corp. on behalf of investors who purchased WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false and misleading statements regarding its business, resulting in significant financial losses for investors. Following GeneDx's Q1 2026 financial results that showed a significant loss and lowered revenue guidance, share prices dropped approximately 50%.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) that they have until August 3, 2026, to file lead plaintiff applications for a securities class action lawsuit. This lawsuit alleges that GeneDx and its executives failed to disclose material information regarding the company's financial performance and the struggles of its Fabric Genomics acquisition, which led to a 49.2% stock price fall after the Q1 2026 financial report. Investors who purchased shares between April 16, 2025, and May 4, 2026, and suffered significant losses are encouraged to contact KSF for legal counsel.
WGS INVESTOR ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made misleading statements regarding the viability of Fabric Genomics, an acquired company, leading to substantial losses for investors. Investors with losses have until August 3, 2026, to seek appointment as lead plaintiff.
GeneDx Holdings Corp. Class Action Lawsuit: Investors Face August 3, 2026, Deadline
Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased shares between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics. Investors have until August 3, 2026, to file for lead plaintiff status.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), advising investors who suffered substantial losses to file lead plaintiff applications by August 3, 2026. The lawsuit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported a drop in adjusted gross margin, missed revenue estimates, and lowered revenue guidance for fiscal year 2026. The company also disclosed a significant impairment loss related to its acquisition of Fabric Genomics, which was touted to expand its market and revenue streams.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
Levi & Korsinsky is reminding shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) about the August 3, 2026 lead plaintiff deadline in a class action lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding its acquisition of Fabric Genomics, which was initially presented as a growth catalyst but resulted in a significant impairment charge and stock drop. Investors who purchased shares between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GeneDx
The Rosen Law Firm is encouraging investors of GeneDx Holdings Corp. (NASDAQ: WGS) to secure legal counsel before the August 3, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that GeneDx made misrepresentations and omissions regarding the impact of its Fabric acquisition on its business and financials. Investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, may be entitled to compensation.
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
Hagens Berman (HBSS) is investigating GeneDx Holdings (WGS) in a securities class action lawsuit following a significant stock collapse and a $31.2 million impairment charge related to its Fabric Genomics acquisition. The suit alleges GeneDx misled investors about the acquisition's synergy potential, leading to dismal Q1 2026 financial results. HBSS urges investors who suffered losses to contact the firm.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
Levi & Korsinsky is reminding shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) about the lead plaintiff deadline of August 3, 2026, in a securities class action lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding its acquisition of Fabric Genomics, which eventually led to a $31.2 million impairment charge and a significant stock drop. Shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, may be eligible to recover losses and are encouraged to contact the firm.
WGS INVESTOR ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made misleading statements regarding the viability of Fabric Genomics, an AI firm it acquired, which led to a significant drop in GeneDx's stock price after the company reported an impairment loss related to the acquisition. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff by August 3, 2026.
ROSEN, A TOP RANKED LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
Rosen Law Firm is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) who purchased common stock between April 16, 2025, and May 4, 2026, about the August 3, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GeneDx made misleading statements about the positive impact of its Fabric acquisition on its financials and operations, which proved to be false. Investors are encouraged to contact the law firm to learn more about joining the class action.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities fraud, encouraging investors who purchased shares between April 16, 2025, and May 4, 2026, to contact the firm. The lawsuit claims GeneDx made false and misleading statements, evidenced by a reported drop in adjusted gross margin, lowered earnings projections, and a significant impairment charge related to Fabric Genomics. Investors have until August 3, 2026, to seek to become lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain officers, alleging federal securities law violations. The lawsuit, covering the period from April 16, 2025, to May 4, 2026, claims GeneDx made materially false and misleading statements regarding its business, operations, and prospects, specifically concerning Fabric Genomics, margins, and reimbursement rates. Investors who suffered losses are encouraged to join the case and may seek to be appointed as lead plaintiff by August 3, 2026.
NASDAQ:WGS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against GeneDx Holdings Corp.
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics, which resulted in a significant drop in GeneDx's share price after the company reported an impairment loss related to Fabric. Investors have until August 3, 2026, to seek lead plaintiff status.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
Rosen Law Firm is encouraging investors of GeneDx Holdings Corp. (NASDAQ: WGS) to secure legal counsel before the August 3, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that GeneDx made misrepresentations and omissions regarding the positive impact of its Fabric acquisition on the company's financials and operations, while allegedly knowing of significant problems with Fabric's viability. Investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, may be entitled to compensation.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, about the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made false statements regarding the viability and positive impact of its Fabric acquisition, which negatively affected the company's business and operations. Investors are encouraged to join the class action to seek compensation.
INVESTOR DEADLINE ALERT: GeneDx Holdings Corp. (WGS) Investors With Substantial Loses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased shares between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false statements regarding the viability of its acquisition of Fabric Genomics. Investors who suffered losses have until August 3, 2026, to seek lead plaintiff status.
Investor Alert: Deadline Approaching to Join GeneDx Holdings Corp. (WGS) Class Action - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of investors who suffered losses due to alleged securities fraud between April 16, 2025, and May 4, 2026. The lawsuit claims that GeneDx made false or misleading statements regarding the viability and financial benefits of its Fabric acquisition. Investors who purchased WGS securities during this period are encouraged to contact the firm to explore their rights to recovery before the deadline.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has initiated a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) due to alleged misrepresentations about its acquisition performance, leading to a 49% stock decline. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF to learn about their legal rights and potentially serve as a lead plaintiff by August 3, 2026. The lawsuit stems from GeneDx's Q1 2026 financial results, which disclosed a significant drop in gross margin, missed revenue estimates, lowered full-year guidance, and a $31.2 million impairment loss related to its Fabric Genomics acquisition.
GeneDx Holdings Corp. Class A Actuals & Estimates (NASDAQ:WGS)
This article provides an overview of GeneDx Holdings Corp. (NASDAQ:WGS) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent financial results such as earnings per share, revenue, and net income, highlighting the significant surprise in last quarter's earnings. The company's volatility, employee count, and upcoming earnings date are also covered.
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
Hagens Berman (HBSS) is investigating potential securities class action claims against GeneDx Holdings (WGS) following a significant stock collapse and a $31.2 million impairment charge related to its Fabric Genomics acquisition. The lawsuit alleges that GeneDx misled investors about the acquisition's synergy potential and future profitability, which was contradicted by dismal Q1 2026 financial results, including a massive tenfold increase in net loss. HBSS is looking into whether the recent appointment of a new President is connected to the alleged failures prior to the May stock drop.
WGS Deadline Alert: The Gross Law Firm Reminds GeneDx
The Gross Law Firm is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a securities class action lawsuit with a lead plaintiff deadline of August 3, 2026. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability and financial benefits of its Fabric acquisition. Shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, are encouraged to contact the firm.
WGS Deadline Alert: The Gross Law Firm Reminds GeneDx Holdings Corp. (WGS) Investors of Securities Class Action Deadline on August 3, 2026
The Gross Law Firm is notifying shareholders of GeneDx Holdings Corp. (WGS) about a securities class action lawsuit deadline on August 3, 2026. The lawsuit alleges that WGS made false and misleading statements regarding the viability and financial benefits of its Fabric acquisition during the period of April 16, 2025, to May 4, 2026, leading to artificially inflated stock prices. Investors who purchased shares during this period are encouraged to contact the firm to potentially be appointed as lead plaintiff.
August 3, 2026 Deadline: Join Class Action Lawsuit Against GeneDx Holdings Corp. (WGS) - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who suffered losses between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made misleading statements regarding the viability and financial benefits of its Fabric acquisition. Shareholders are encouraged to contact the firm by the August 3, 2026, deadline to explore potential recovery.
ROSEN, NATIONALLY REGARDED LAWYERS, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
Rosen Law Firm is encouraging investors of GeneDx Holdings Corp. (NASDAQ: WGS) to secure legal counsel before the August 3, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the positive impact of its Fabric acquisition on the company's financials and operations, while concealing significant viability problems. Investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, may be entitled to compensation.
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced that investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements and failed to disclose significant problems with Fabric Genomics, an acquired company, which negatively impacted GeneDx's business and resulted in a substantial drop in stock price. Investors can contact the firm for more information on how to participate.
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS
GeneDx Holdings (WGS) is facing a securities class action lawsuit after a significant stock drop following its Q1 2026 earnings report. The lawsuit alleges that GeneDx made misleading statements regarding the acquisition of Fabric Genomics, its financial performance, and average reimbursement rates. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact Hagens Berman to discuss their rights.
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS
GeneDx Holdings (NASDAQ: WGS) is facing a securities class action lawsuit after its stock price fell 49% following a dismal Q1 2026 earnings report, which included a 94% write-off of its Fabric Genomics acquisition. The lawsuit, brought by Hagens Berman, alleges that GeneDx misled investors about the value of Fabric Genomics and the durability of its average reimbursement rates, leading to a significant drop in its stock value. Investors who purchased shares between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. This suit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported disappointing Q1 2026 financial results, including a drop in adjusted gross margin and a lowered full-year revenue guidance. The lawsuit also highlights a significant impairment loss related to the acquisition of Fabric Genomics, which was previously touted as a growth driver.
Robbins LLP Urges WGS Stockholders Who Lost Money Investing in GeneDx Holdings Corp. to Contact the Firm for Information About Leading the Class Action
Robbins LLP is informing stockholders of GeneDx Holdings Corp. (NASDAQ: WGS) about a class action lawsuit filed against the company. The lawsuit alleges that GeneDx misled investors regarding the positive impact of its acquisition of Fabric Genomics, stating that the company knew about significant problems with Fabric's viability. Shareholders who purchased WGS common stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact Robbins LLP to learn more about leading the class action.
